Armata Pharmaceuticals, Inc. (ARMP) — Analyst outlook / Analyst consensus target is. Based on 4 analyst ratings, the consensus is bullish — 4 Buy.
The consensus price target is $15.00, representing an upside of 16.5% from the current price $12.88.
Analysts estimate Earnings Per Share (EPS) of $-0.95 and revenue of $0.01B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.52 vs est $-0.95 (beat +45.3%). 2025: actual $-4.80 vs est $-1.64 (missed -193.6%). Analyst accuracy: 26%.
ARMP Stock — 12-Month Price Forecast
$15.00
▲ +16.46% Upside
Average Price Target
Based on 4 Wall Street analysts offering 12-month price targets for Armata Pharmaceuticals, Inc., the price target is $15.00.
The average price target represents a +16.46% change from the last price of $12.88.
ARMP Analyst Ratings
Buy
Based on 4 analysts giving stock ratings to Armata Pharmaceuticals, Inc. in the past 3 months
EPS Estimates — ARMP
26%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$0.52
vs Est –$0.95
▲ 82.7% off
2025
Actual –$4.80
vs Est –$1.64
▼ 65.9% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — ARMP
93%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.005B
vs Est $0.006B
▼ 6.3% off
2025
Actual $0.005B
vs Est $0.005B
▲ 7.2% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
